Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832

Watchlist Manager
Shenzhen New Industries Biomedical Engineering Co Ltd Logo
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Watchlist
Price: 61.88 CNY -2.35% Market Closed
Market Cap: 48.6B CNY
Have any thoughts about
Shenzhen New Industries Biomedical Engineering Co Ltd?
Write Note

Net Margin
Shenzhen New Industries Biomedical Engineering Co Ltd

42.3%
Current
41%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
42.3%
=
Net Income
1.8B
/
Revenue
4.3B

Net Margin Across Competitors

Country CN
Market Cap 48.6B CNY
Net Margin
42%
Country JP
Market Cap 6.8T JPY
Net Margin
24%
Country CH
Market Cap 37.9B CHF
Net Margin
12%
Country DK
Market Cap 200.9B DKK
Net Margin
19%
Country US
Market Cap 16.9B USD
Net Margin
11%
Country KR
Market Cap 9.9T KRW
Net Margin
-358%
Country CA
Market Cap 6.9B USD
Net Margin
-8%
Country US
Market Cap 6.3B USD
Net Margin
29%
Country US
Market Cap 6.1B USD
Net Margin
9%
Country UK
Market Cap 4.8B GBP
Net Margin
7%
Country CH
Market Cap 4.9B CHF
Net Margin
12%
No Stocks Found

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Market Cap
48.6B CNY
Industry
Health Care

Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIB) stands at the forefront of innovation in the biomedical sector, specializing in the development and manufacturing of cutting-edge medical devices and diagnostic solutions. Founded in a thriving economic hub, Shenzhen, the company harnesses state-of-the-art technology and research expertise to deliver products that enhance healthcare outcomes. With a robust portfolio that spans various therapeutic areas, including critical care, cardiology, and infectious diseases, SNIB is not only committed to advancing healthcare but also to addressing pressing global health challenges. Their dedication to research and development, coupled with strategic partnerships with leading research institutions, positions them as a significant player in the rapidly expanding biomedical market. For investors, SNIB represents a compelling opportunity driven by a combination of strong growth potential and strategic ambition. The company has consistently demonstrated impressive revenue growth, complemented by a commitment to innovation, which has resulted in a growing pipeline of products that meet both current and emerging healthcare needs. With the rising demand for advanced medical solutions globally, SNIB is poised to leverage its technological strengths and market position to capture an increasing share of this burgeoning industry. Additionally, the company's proactive approach to regulatory compliance and quality assurance underscores its commitment to delivering safe and effective products, further enhancing investor confidence in its long-term viability and success.

Intrinsic Value
86.51 CNY
Undervaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
42.3%
=
Net Income
1.8B
/
Revenue
4.3B
What is the Net Margin of Shenzhen New Industries Biomedical Engineering Co Ltd?

Based on Shenzhen New Industries Biomedical Engineering Co Ltd's most recent financial statements, the company has Net Margin of 42.3%.